Cartesian reports positive results from Phase IIb myasthenia gravis trial [Yahoo! Finance]
Cartesian Therapeutics, Inc. (RNAC)
Company Research
Source: Yahoo! Finance
chimeric antigen receptor T-cell therapy (mRNA CAR-T), in patients with generalised myasthenia gravis (MG). The double-blind, crossover, placebo-controlled trial involved 36 heavily pre-treated, highly symptomatic MG patients. They were randomised into a 1:1 ratio to receive either Descartes-08 or a placebo as six weekly outpatient infusions, without preconditioning chemotherapy. After the blinded follow-up in the third month, placebo recipients were offered the option to switch over to the Descartes-08 treatment. The proportion of patients achieving a reduction of five points or more in the MG Composite (MGC) score was the primary efficacy endpoint. Secondary endpoints included safety, tolerability, and other validated MG severity scales. According to the findings, the trial met its primary efficacy endpoint of statistical significance, with 71% of subjects in the Descartes-08 arm reported to have five-point or greater improvements in the MGC score at month three, versus
Show less
Read more
Impact Snapshot
Event Time:
RNAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNAC alerts
High impacting Cartesian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RNAC
News
- Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates [Yahoo! Finance]Yahoo! Finance
- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its price target lowered by analysts at HC Wainwright from $54.00 to $49.00. They now have a "buy" rating on the stock.MarketBeat
- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its price target raised by analysts at Canaccord Genuity Group Inc. from $38.00 to $43.00. They now have a "buy" rating on the stock.MarketBeat
- Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik [Yahoo! Finance]Yahoo! Finance
- Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal MalikGlobeNewswire
RNAC
Earnings
- 5/8/24 - Miss
RNAC
Sec Filings
- 7/5/24 - Form SC
- 7/5/24 - Form 4
- 7/3/24 - Form 4
- RNAC's page on the SEC website